| Symbol | SLS |
|---|---|
| Name | SELLAS LIFE SCIENCES GROUP, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 15 WEST 38TH STREET,10TH FLOOR, NEW YORK, New York, 10017, United States |
| Telephone | +1 917 438-4353 |
| Fax | — |
| — | |
| Website | https://www.sellaslifesciences.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001390478 |
| Description | SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax. Additional info from NASDAQ: |
(30% Negative) SELLAS LIFE SCIENCES GROUP, INC. (SLS) Reports Q3 2026 Financial Results
Read moreSellas Life Sciences - SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read moreNew Form SCHEDULE 13G - SELLAS Life Sciences Group, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000539 <b>Size:</b> 8 KB
Read moreNew Form SCHEDULE 13G - SELLAS Life Sciences Group, Inc. <b>Filed:</b> 2026-07-31 <b>AccNo:</b> 0002100119-26-001315 <b>Size:</b> 7 KB
Read more(99% Neutral) SELLAS LIFE SCIENCES GROUP, INC. (SLS) Reports Q3 2026 Financial Results
Read more(99% Neutral) SELLAS LIFE SCIENCES GROUP, INC. (SLS) Announces New Board Appointment
Read moreNew Form S-8 - SELLAS Life Sciences Group, Inc. <b>Filed:</b> 2026-06-16 <b>AccNo:</b> 0001104659-26-074599 <b>Size:</b> 356 KB
Read more(99% Neutral) SELLAS LIFE SCIENCES GROUP, INC. (SLS) Provides Business Update
Read moreSellas Life Sciences - SELLAS Life Sciences to Participate in Upcoming Investor Conferences
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05593185 | Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed Wi… | — | Acute Myeloid Leukemia | Available | — | — | ClinicalTrials.gov |
| NCT04588922 | Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in P… | Phase1 | Hematologic Malignancies | Recruiting | 2021-05-10 | 2027-12-31 | ClinicalTrials.gov |
| NCT04229979 | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maint… | Phase3 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2021-02-08 | 2026-12-01 | ClinicalTrials.gov |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Adva… | Phase1 | Acute Myelogenous Leukemia | Completed | 2019-09-30 | 2022-10-27 | ClinicalTrials.gov |
| NCT02297698 | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High… | Phase2 | Breast Cancer | Completed | 2014-10-01 | 2021-12-01 | ClinicalTrials.gov |
| NCT01570036 | Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | Phase2 | Breast Cancer | Completed | 2013-05-21 | 2018-09-28 | ClinicalTrials.gov |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem C… | Phase1 | Multiple Myeloma | Completed | 2013-04-01 | 2017-11-06 | ClinicalTrials.gov |
| NCT01266083 | WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML… | Phase2 | Acute Myeloid Leukemia | Completed | 2011-01-14 | 2016-09-30 | ClinicalTrials.gov |
| NCT01265433 | Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma … | Phase2 | Malignant Pleural Mesothelioma | Completed | 2010-12-21 | 2017-07-25 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| GM-CSF | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01570036 |
| NeuVax vaccine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01570036 |
| Herceptin | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT01570036 |
| GM-CSF | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02297698 |
| Trastuzumab | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02297698 |
| NeuVax vaccine | Other | Phase PHASE2 | Breast Cancer | COMPLETED | NCT02297698 |
| bortezomib | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01827137 |
| lenalidomide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01827137 |
| Montanide | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01827137 |
| GM-CSF | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01827137 |
| Galinpepimut-S | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT01827137 |
| Montanide + GM-CSF | Other | Phase PHASE2 | Malignant Pleural Mesothelioma | COMPLETED | NCT01265433 |
| Galinpepimut-S + Montanide + GM-CSF | Other | Phase PHASE2 | Malignant Pleural Mesothelioma | COMPLETED | NCT01265433 |
| GM-CSF | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT03761914 |
| Montanide | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT03761914 |
| pembrolizumab | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT03761914 |
| galinpepimut-S | Other | Phase PHASE1 | Acute Myelogenous Leukemia | COMPLETED | NCT03761914 |
| Montanide | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT01266083 |
| GM-CSF | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT01266083 |
| Galinpepimut-S | Other | Phase PHASE2 | Acute Myeloid Leukemia | COMPLETED | NCT01266083 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Montanide | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04229979 |
| GM-CSF | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04229979 |
| Observation | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04229979 |
| Cytarabine | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04229979 |
| Decitabine | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04229979 |
| Venetoclax | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04229979 |
| Azacitidine | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04229979 |
| Galinpepimut-S | Other | Phase PHASE3 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT04229979 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| azacitidine | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| venetoclax | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| SLS009 | Other | Phase PHASE1 | Hematologic Malignancies | RECRUITING | NCT04588922 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |
| Galinpepimut-S | Other | Preclinical | Acute Myeloid Leukemia | AVAILABLE | NCT05593185 |